20 mg · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Lumbrokinase is a group of bioactive proteolytic enzymes (25–32 kDa) extracted from the earthworm Lumbricus rubellus. First identified in the early 1990s, it contains plasminogen activator and plasmin-like enzymes that dissolve fibrin clots. Unlike streptokinase or urokinase, lumbrokinase exhibits thrombolytic activity only in the presence of fibrin, minimising bleeding risk. It has been used clinically in China for stroke and cardiovascular disease since the 1990s.
Lumbrokinase converts plasminogen to plasmin by increasing endogenous t-PA activity, then directly degrades fibrin clots. Its fibrin-specific activity means it targets existing thrombi without causing systemic fibrinolysis and bleeding. A 2013 multicenter RCT in 310 stroke patients showed that one-year oral lumbrokinase therapy reduced carotid IMT, vulnerable plaque volume, and total vascular events (6.78% vs 2.08%) compared to standard care. A meta-analysis of two RCTs in peripheral arterial disease showed significant increases in ankle-brachial index.
Individuals with elevated fibrinogen or hypercoagulability seeking natural fibrinolytic support. Those with cardiovascular risk factors wanting adjunctive circulatory support. People with peripheral arterial disease. Not a replacement for prescription anticoagulants in acute thrombosis.
Individuals on warfarin, heparin, or direct oral anticoagulants without medical supervision. Those with bleeding disorders or active bleeding. Pregnant and breastfeeding women. People with severe liver disease. Not for children. Discontinue 2 weeks before surgery. Side effects: Generally well-tolerated. Mild gastrointestinal upset at higher doses. Theoretical bleeding risk if combined with anticoagulants — monitor closely. Rare allergic reactions.
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 24229674 (stroke RCT, n=310), PMID 8263976 (PAD meta-analysis), PMID 6013847 (Sirt1 activation and cardioprotection in I-R injury), PMID 15532307 (exercise tolerance in CHD)
SacredBod's longer take on Lumbrokinase — context the structured blocks above don't capture.
Lumbrokinase is a group of bioactive proteolytic enzymes (25–32 kDa) extracted from the earthworm Lumbricus rubellus. First identified in the early 1990s, it contains plasminogen activator and plasmin-like enzymes that dissolve fibrin clots. Unlike streptokinase or urokinase, lumbrokinase exhibits thrombolytic activity only in the presence of fibrin, minimising bleeding risk. It has been used clinically in China for stroke and cardiovascular disease since the 1990s.
Lumbrokinase converts plasminogen to plasmin by increasing endogenous t-PA activity, then directly degrades fibrin clots. Its fibrin-specific activity means it targets existing thrombi without causing systemic fibrinolysis and bleeding. A 2013 multicenter RCT in 310 stroke patients showed that one-year oral lumbrokinase therapy reduced carotid IMT, vulnerable plaque volume, and total vascular events (6.78% vs 2.08%) compared to standard care. A meta-analysis of two RCTs in peripheral arterial disease showed significant increases in ankle-brachial index.
Individuals with elevated fibrinogen or hypercoagulability seeking natural fibrinolytic support. Those with cardiovascular risk factors wanting adjunctive circulatory support. People with peripheral arterial disease. Not a replacement for prescription anticoagulants in acute thrombosis.
Typical dose: 20 mg per day
Form: capsules (60 count)
Best time: morning
With food: empty-stomach
Expected onset: 2–4 weeks for fibrinogen reduction; 4–8 weeks for cardiovascular benefits
Cycling: No cycling required. Can be taken continuously under medical supervision.
Known side effects: Generally well-tolerated. Mild gastrointestinal upset at higher doses. Theoretical bleeding risk if combined with anticoagulants — monitor closely. Rare allergic reactions.
Who should avoid: Individuals on warfarin, heparin, or direct oral anticoagulants without medical supervision. Those with bleeding disorders or active bleeding. Pregnant and breastfeeding women. People with severe liver disease. Not for children. Discontinue 2 weeks before surgery.
Avoid combining with: Warfarin and anticoagulants, Aspirin and antiplatelets, NSAIDs, Nattokinase and serrapeptase (redundant fibrinolytics), Fish oil at high doses (additive bleeding risk)
Lumbrokinase is available on Amazon India with varying brand quality. When selecting a product, verify standardization claims against the evidence base cited above. Indian brand preferences include Carbamide Forte, HealthyHey, Nutrabay Pure, Pure Nutrition, Now Foods, Nutricost, Himalaya, Patanjali, Dabur, Trexgenics, Evorina, Nervana, Life Extension, VITARUHE, ASTERVEDA, BECLEC, GreenOpia, Rasayanam, Zyrex, and Shree Herbal. Prices vary significantly; compare cost-per-active-dose rather than capsule count alone.
Schedule status in India: Not a Schedule H drug; available as dietary supplement/herbal product.
Key citations: PMID 24229674 (stroke RCT, n=310), PMID 8263976 (PAD meta-analysis), PMID 6013847 (Sirt1 activation and cardioprotection in I-R injury), PMID 15532307 (exercise tolerance in CHD)
Evidence grade: B — n=310 in largest stroke RCT; meta-analysis of PAD trials
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
